🇺🇸 FDA
Pipeline program

CEP-701 20mg

C0701/2024/DR/US

Phase 2 small_molecule completed

Quick answer

CEP-701 20mg for Psoriasis is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Psoriasis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials